WO2006060190A3 - Imidazole derivatives - Google Patents

Imidazole derivatives Download PDF

Info

Publication number
WO2006060190A3
WO2006060190A3 PCT/US2005/041895 US2005041895W WO2006060190A3 WO 2006060190 A3 WO2006060190 A3 WO 2006060190A3 US 2005041895 W US2005041895 W US 2005041895W WO 2006060190 A3 WO2006060190 A3 WO 2006060190A3
Authority
WO
WIPO (PCT)
Prior art keywords
imidazole derivatives
modulation
useful
relates
treating diseases
Prior art date
Application number
PCT/US2005/041895
Other languages
French (fr)
Other versions
WO2006060190A2 (en
Inventor
Zahra Fathi
Original Assignee
Bayer Pharmaceuticals Corp
Zahra Fathi
Priority date (The priority date is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the date listed.)
Filing date
Publication date
Application filed by Bayer Pharmaceuticals Corp, Zahra Fathi filed Critical Bayer Pharmaceuticals Corp
Publication of WO2006060190A2 publication Critical patent/WO2006060190A2/en
Publication of WO2006060190A3 publication Critical patent/WO2006060190A3/en

Links

Classifications

    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K31/00—Medicinal preparations containing organic active ingredients
    • A61K31/33—Heterocyclic compounds
    • A61K31/395—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins
    • A61K31/41—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins having five-membered rings with two or more ring hetero atoms, at least one of which being nitrogen, e.g. tetrazole
    • A61K31/4164—1,3-Diazoles
    • A61K31/4172—Imidazole-alkanecarboxylic acids, e.g. histidine

Abstract

This invention relates to imidazole derivatives which are useful in treating diseases linked to the modulation of the cannabinoid receptors.
PCT/US2005/041895 2004-11-30 2005-11-18 Imidazole derivatives WO2006060190A2 (en)

Applications Claiming Priority (2)

Application Number Priority Date Filing Date Title
US63201204P 2004-11-30 2004-11-30
US60/632,012 2004-11-30

Publications (2)

Publication Number Publication Date
WO2006060190A2 WO2006060190A2 (en) 2006-06-08
WO2006060190A3 true WO2006060190A3 (en) 2007-08-02

Family

ID=36565529

Family Applications (1)

Application Number Title Priority Date Filing Date
PCT/US2005/041895 WO2006060190A2 (en) 2004-11-30 2005-11-18 Imidazole derivatives

Country Status (1)

Country Link
WO (1) WO2006060190A2 (en)

Families Citing this family (1)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
WO2024009283A1 (en) * 2022-07-07 2024-01-11 University Of Southern California At2 antagonists for non-addictive pain relief

Citations (6)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
US6492516B1 (en) * 1999-05-14 2002-12-10 Merck & Co., Inc. Compounds having cytokine inhibitory activity
WO2003027076A2 (en) * 2001-09-21 2003-04-03 Solvay Pharmaceuticals B.V. 1h-imidazole derivatives having cb1 agonistic, cb1 partial agonistic or cb1- antagonistic activity
US20040122074A1 (en) * 2002-12-12 2004-06-24 Pfizer Inc. Cannabinoid receptor ligands and uses thereof
US20040248956A1 (en) * 2002-01-29 2004-12-09 Hagmann William K Substituted imidazoles as cannabinoid receptor modulators
US20050026983A1 (en) * 2003-07-30 2005-02-03 Pfizer Inc Imidazole compounds and uses thereof
US6960601B2 (en) * 2001-09-24 2005-11-01 Bayer Pharmaceuticals Corporation Preparation and use of imidazole derivatives for treatment of obesity

Patent Citations (6)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
US6492516B1 (en) * 1999-05-14 2002-12-10 Merck & Co., Inc. Compounds having cytokine inhibitory activity
WO2003027076A2 (en) * 2001-09-21 2003-04-03 Solvay Pharmaceuticals B.V. 1h-imidazole derivatives having cb1 agonistic, cb1 partial agonistic or cb1- antagonistic activity
US6960601B2 (en) * 2001-09-24 2005-11-01 Bayer Pharmaceuticals Corporation Preparation and use of imidazole derivatives for treatment of obesity
US20040248956A1 (en) * 2002-01-29 2004-12-09 Hagmann William K Substituted imidazoles as cannabinoid receptor modulators
US20040122074A1 (en) * 2002-12-12 2004-06-24 Pfizer Inc. Cannabinoid receptor ligands and uses thereof
US20050026983A1 (en) * 2003-07-30 2005-02-03 Pfizer Inc Imidazole compounds and uses thereof

Non-Patent Citations (1)

* Cited by examiner, † Cited by third party
Title
LANGE J.H.M. ET AL.: "Bioisosteric Replacement of the Pyrazole Moiety of Rimonabant: Synthesis, Bioligical Properties, and Molecular Modeling Investigation of Thiazoles, Triazoles, and Imidazoles as Potent and Selective CB1 Cannabinoid Receptor Antagonists", J. MED. CHEM., vol. 48, 2005, pages 1823 - 1838, XP002339942 *

Also Published As

Publication number Publication date
WO2006060190A2 (en) 2006-06-08

Similar Documents

Publication Publication Date Title
WO2007076070A3 (en) Modulators of muscarinic receptors
WO2009052431A3 (en) Cd19 binding agents and uses thereof
WO2007150015A3 (en) Method of treatment
WO2008027812A3 (en) Imidazopyridine and imidazopyrimidine derivatives
WO2005062916A3 (en) Methods for generating multimeric molecules
WO2006113919A3 (en) Aryl alkyl acid derivatives for and use thereof
WO2009002947A3 (en) Compounds and peptides that bind the trail receptor
WO2008097461A3 (en) Hepcidin and hepcidin antibodies
WO2007020502A3 (en) Cannabinoid receptor ligands and uses thereof
WO2006023852A3 (en) Modulators of muscarinic receptors
WO2008133722A3 (en) Anti human sclerostin antibodies
WO2007021937A3 (en) Unsaturated heterocyclic derivatives
WO2005000820A3 (en) 4-cyanopyrazole-3-carboxamide derivatives preparation and application thereof as cb1 cannabinoid antagonists
NO20081788L (en) Cyclopropylamines as modulators of the histamine H3 receptor
IL184006A0 (en) 1h-imidiazole derivatives as cannabinoid
MX2009009415A (en) Tetrahydroisoquinoline compounds as modulators of the histamine h3 receptor.
WO2006058294A3 (en) Modulators of muscarinic receptors
MY146506A (en) Substituted pyridyl amide compounds as modulators of the histamine h3 receptor
WO2007022947A3 (en) 5-ring heteroaromatic compounds and their use as binding partners for 5-ht5 receptors
WO2009071689A3 (en) 5-halogen-substituted oxindole derivatives and use thereof for treating vasopressine-dependent diseases
WO2005030188A3 (en) Phenyl-piperazine derivatives as modulators of muscarinic receptors
WO2008112192A3 (en) Epha3 antibodies for the treatment of solid tumors
WO2005110491A3 (en) Inducible dimerization of growth factor receptors for treating cancer
WO2008021375A3 (en) Modulators of muscarinic receptors
WO2006058303A3 (en) Modulators of muscarinic receptors

Legal Events

Date Code Title Description
AK Designated states

Kind code of ref document: A2

Designated state(s): AE AG AL AM AT AU AZ BA BB BG BR BW BY BZ CA CH CN CO CR CU CZ DE DK DM DZ EC EE EG ES FI GB GD GE GH GM HR HU ID IL IN IS JP KE KG KM KN KP KR KZ LC LK LR LS LT LU LV LY MA MD MG MK MN MW MX MZ NA NG NI NO NZ OM PG PH PL PT RO RU SC SD SE SG SK SL SM SY TJ TM TN TR TT TZ UA UG US UZ VC VN YU ZA ZM ZW

AL Designated countries for regional patents

Kind code of ref document: A2

Designated state(s): GM KE LS MW MZ NA SD SL SZ TZ UG ZM ZW AM AZ BY KG KZ MD RU TJ TM AT BE BG CH CY CZ DE DK EE ES FI FR GB GR HU IE IS IT LT LU LV MC NL PL PT RO SE SI SK TR BF BJ CF CG CI CM GA GN GQ GW ML MR NE SN TD TG

121 Ep: the epo has been informed by wipo that ep was designated in this application
NENP Non-entry into the national phase

Ref country code: DE

122 Ep: pct application non-entry in european phase

Ref document number: 05848929

Country of ref document: EP

Kind code of ref document: A2